Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

BIBP-3226

From Wikipedia, the free encyclopedia
Chemical compound

Pharmaceutical compound
BIBP-3226
Clinical data
Other namesBIBP-3226
Identifiers
  • (2R)-5-(diaminomethylideneamino)-2-([2,2-diphenylacetyl]amino)-N-[(4-hydroxyphenyl)methyl]pentanamide
CAS Number
PubChemCID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC27H31N5O3
Molar mass473.577 g·mol−1
3D model (JSmol)
  • C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC3=CC=C(C=C3)O
  • InChI=1S/C27H31N5O3/c28-27(29)30-17-7-12-23(25(34)31-18-19-13-15-22(33)16-14-19)32-26(35)24(20-8-3-1-4-9-20)21-10-5-2-6-11-21/h1-6,8-11,13-16,23-24,33H,7,12,17-18H2,(H,31,34)(H,32,35)(H4,28,29,30)/t23-/m1/s1 checkY
  • Key:KUWBXRGRMQZCSS-HSZRJFAPSA-N checkY
 ☒NcheckY (what is this?)  (verify)

BIBP-3226 is a drug used in scientific research which acts as a potent and selectiveantagonist for both theNeuropeptide Y receptorY1[1] and also theneuropeptide FF receptor.[2] It was the first non-peptide antagonist developed for the Y1 receptor and has been widely used to help determine its functions in the body. Activation of Y1 is thought to be involved in functions such as regulation of appetite[3] and anxiety,[4] and BIBP-3226 hasanxiogenic[5] andanorectic effects, as well as blocking the Y1-mediatedcorticotropin releasing hormone release.[6] It has also been used as alead compound to develop a number of newer more potent Y1 antagonists.[7][8]

References

[edit]
  1. ^Rudolf K, Eberlein W, Engel W, Wieland HA, Willim KD, Entzeroth M, Wienen W, Beck-Sickinger AG, Doods HN (December 1994). "The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226".European Journal of Pharmacology.271 (2–3): R11–3.doi:10.1016/0014-2999(94)90822-2.PMID 7705422.
  2. ^Fang Q, Guo J, He F, Peng YL, Chang M, Wang R (September 2006). "In vivo inhibition of neuropeptide FF agonism by BIBP3226, an NPY Y1 receptor antagonist".Peptides.27 (9):2207–13.doi:10.1016/j.peptides.2006.04.002.PMID 16762456.S2CID 34414256.
  3. ^Kask A, Rägo L, Harro J (August 1998)."Evidence for involvement of neuropeptide Y receptors in the regulation of food intake: studies with Y1-selective antagonist BIBP3226".British Journal of Pharmacology.124 (7):1507–15.doi:10.1038/sj.bjp.0701969.PMC 1565528.PMID 9723965.
  4. ^Kask A, Harro J, von Hörsten S, Redrobe JP, Dumont Y, Quirion R (May 2002). "The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y".Neuroscience and Biobehavioral Reviews.26 (3):259–83.doi:10.1016/S0149-7634(01)00066-5.PMID 12034130.S2CID 34688422.
  5. ^Kask A, Rägo L, Harro J (September 1998). "Anxiogenic-like effect of the NPY Y1 receptor antagonist BIBP3226 administered into the dorsal periaqueductal gray matter in rats".Regulatory Peptides.75–76:255–62.doi:10.1016/S0167-0115(98)00076-7.PMID 9802417.S2CID 19193956.
  6. ^Dimitrov EL, DeJoseph MR, Brownfield MS, Urban JH (August 2007)."Involvement of neuropeptide Y Y1 receptors in the regulation of neuroendocrine corticotropin-releasing hormone neuronal activity".Endocrinology.148 (8):3666–73.doi:10.1210/en.2006-1730.PMID 17463058.
  7. ^Aiglstorfer I, Hendrich I, Moser C, Bernhardt G, Dove S, Buschauer A (July 2000). "Structure-activity relationships of neuropeptide Y Y1 receptor antagonists related to BIBP 3226".Bioorganic & Medicinal Chemistry Letters.10 (14):1597–600.doi:10.1016/S0960-894X(00)00292-4.PMID 10915060.
  8. ^Weiss S, Keller M, Bernhardt G, Buschauer A, König B (November 2008). "Modular synthesis of non-peptidic bivalent NPY Y1 receptor antagonists".Bioorganic & Medicinal Chemistry.16 (22):9858–66.doi:10.1016/j.bmc.2008.09.033.PMID 18851917.


Stub icon

Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=BIBP-3226&oldid=1269665718"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp